Abstract:Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether F-18-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)- 2-hydroxy-3-fluoropropane [F-18-FMISO]) PET/CT could predict primary resistance to hormonal therapy in ER-positive breast cancer. Methods: Postmenopausal women who had ER-a-positive breast cancer, stages II-IV, and had never received prior endocrine therapy were prospectively enrolled in this study. Patients underwent both F-18-FDG and F-18-FMISO PET/CT scans before and after treatment. The hottest F-18-FDG standardized uptake value (SUV) in the tumor foci, the SUVs at 2 and 4 h, and the TBR2 h and TBR4 h for the target lesions were calculated (TBR2 h - SUV2 h(T)/SUV2 h(B) and TBR4 h = SUV4 h(T)/SUV4 h(B) [TBR is the tumor-to-background ratio]). Clinical outcomes of primary endocrine therapy with letrozole were evaluated according to the criteria of the World Health Organization after at least 3 mo of treatment. Immunohistochemistry for markers of proliferation (Ki67) and hypoxia-induced factor 1 alpha was performed on a subset of tumors that had undergone biopsy or surgery. Pearson and Spearman analysis was used to determine the correlation between the parameters of F-18-FDG and F-18-FMISO uptake and clinical or immunohistochemistry outcomes with a 0.01 threshold for statistical significance. Results: A total of 45 lesions (13 primary, 32 metastatic) from 20 patients met the inclusion criteria in this study. Baseline F-18-FDG and F-18-FMISO PET/CT scans were obtained for 33 lesions from 16 patients. The correlation between baseline F-18-FDG uptake and clinical outcome was weak and did not reach statistical significance (r = 0.37, P = 0.031). However, there was a significantly positive correlation between baseline F-18-FMISO uptake (SUV2 h(T), TBR2 h, SUV4 h(T), and TBR4 h) and clinical outcomes after >= 3 mo of primary endocrine therapy with letrozole (r = 0.77, 0.76, 0.71, and 0.78, respectively; P < 0.0001). The application of a TBR4 h cutoff of >= 1.2 allowed the prediction of 88% of the cases of progressive disease (15/17). Despite poor correlation between F-18-FMISO uptake and hypoxia-induced factor 1 alpha expression, a marginal positive correlation between TBR4 h and Ki67 expression was measured (r = 0.51, P = 0.011) in a subset of malignant lesions acquired by biopsy or surgery. Conclusion: F-18-FMISO PET/CT can be used to predict primary endocrine resistance in ER-positive breast cancer.

DRD2 expression based on <SUP>18</SUP>F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study

DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: A pilot study

Noninvasive radiomics approach predicts dopamine agonists treatment response in patients with prolactinoma: a multicenter study

Association Between Polymorphism of Dopamine D2 Receptor Genes and Therapeutic Effect of Domperidone in Functional Dyspepsia.

Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior

Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs

Correlation of Alternative Splicing of the D2 Dopamine Receptor Mrna and Estrogen Receptor Mrna in the Prolactinomas and Gonadotrope Tumors

Brain Imaging of Dopamine D2/D3 Receptors of 18F-Fallypride-pet in Normal Volunteers: an Amic Ray-Scan 64 Pet/Ct Clinical System Clinical Trial

[A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease].

Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas

The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists

Evaluation of the early response and mechanism of treatment of Parkinson's disease with L-dopa using 18F-fallypride micro-positron emission tomography scanning

Correlation between resistance to bromocriptine and plasma prolactin level in patients with prolactinoma.

Predicting the Dopamine D2 Receptor Occupancy of Ropinirole in Rats Using Positron Emission Tomography and Pharmacokinetic–pharmacodynamic Modeling

Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal

Expressions and significance of DAT and D2R in pituitary adenoma tissues

The Expression Profile of Dopamine D2 Receptor, Mgmt and Vegf in Different Histological Subtypes of Pituitary Adenomas: A Study of 197 Cases and Indications for the Medical Therapy

Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18 F-FDG PET

18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer

R & D Trends of New Drugs for PET/CT Brain Imaging and R & D of New Drugs for Brain Imaging Based on the PET/CT System

The Side Effects of Dopamine Receptor Agonist Drugs in Chinese Prolactinoma Patients: a Cross Sectional Study